The mechanism by which transforming growth factor-␤1 (TGF-␤1) induces apoptosis of prostate epithelial cells was studied in the NRP-154 rat prostate epithelial cell line. TGF-␤1 down-regulates expression of Bcl-xL and poly(ADP-ribosyl)polymerase (PARP), promotes cytochrome c release, up-regulates expression of latent caspase-3, and activates caspases 3 and 9. We tested the role of Bcl-xL in this cascade by stably overexpressing Bcl-xL to prevent loss by TGF-␤1. Clones overexpressing Bcl-xL are resistant to TGF-␤1 with respect to induction of apoptosis, cytochrome c release, activation of caspases 9 and 3, and cleavage of PARP; yet they remain sensitive to TGF-␤1 by cell cycle arrest, induction of both fibronectin and latent caspase-3 expression, and loss of PARP expression. We show that Bcl-xL associates with Apaf-1 in NRP-154 cells; but this association does not inhibit the activation of caspases 9 and 3 by cytochrome c. Together, our data suggest that TGF-␤1 induces apoptosis through loss of Bcl-xL, leading to cytochrome c release and the subsequent activation of caspases 9 and 3. Moreover, our data demonstrate that the antiapoptotic effect of Bcl-xL occurs by inhibition of mitochondrial cytochrome c release and not through antagonizing Apaf-1-dependent processing of caspases 9 and 3.
which then engages a dimeric type I receptor (T␤RI) to form a receptor-ligand heteromeric complex (reviewed in Refs. 4 -7) . The constitutively activated T␤RII kinase then transactivates T␤RI by phosphorylation. Activated T␤RI phosphorylates signal transducers Smads 2 and 3, which then translocate to the nucleus, often in association with Smad 4, and regulate target gene expression (reviewed in Refs. 8 -10) ). It is becoming increasingly apparent that many other participants, particularly serine/threonine kinases (TGF-␤1-activated kinase/TGF-␤1-activated kinase-binding protein, extracellular receptor kinase, stress-activated protein kinase/c-Jun N-terminal protein kinase), are involved in TGF-␤1 signaling (11) (12) (13) (14) (15) (16) . How the TGF-␤1 ligand-receptor complex activates the above kinases and what interactions with Smad proteins mediate differentiation, growth arrest, and apoptosis are poorly understood and under intense investigation.
Apoptosis is critical for development and maintenance of tissues in multicellular organisms. Perturbations of apoptosis often result in several disease states (17) (18) (19) ; therefore, understanding the molecular mechanisms of apoptosis serves as an impetus for therapeutic benefit. Genetic studies from Caenorhabditis elegans have identified several key regulators of apoptosis: CED-3, CED-4, and CED-9 (20, 21) . The mammalian homologue of CED-9, Bcl-xL, has been implicated as a major apoptotic regulator in many mammalian tissues including the prostate (22) (23) (24) .
Several hypotheses offer potential mechanisms of how Bcl-xL exerts its pro-survival effects. Bcl-xL is structurally similar to the pore-forming domains of diphtheria toxin and colicins, suggesting that it may function as, or in association with, a mitochondrial ion channel to regulate apoptosis (25) (26) (27) . Previous reports implicate Bcl-xL as a facilitator of ADP supply to the mitochondrial matrix, allowing for continued F 1 F 0 -ATPase activity (28) . It is suggested that once mitochondrial respiration terminates through loss of F 1 F 0 -ATPase activity, mitochondrial release of cytochrome c occurs, and the apoptotic pathway is engaged (29) . Negative regulation of cytochrome c release by Bcl-xL has been demonstrated by physical interaction with components of the voltage-dependent anion channel via a mechanism inhibited by several pro-apoptotic Bcl-2 members (30 -35) . Further evidence shows that Bcl-xL is a regulator of the apoptosome and may antagonize the Apaf-1 association and activation of pro-caspase-9 (36) .
The normal prostatic epithelium undergoes extensive apoptosis following androgen ablation, concomitant with induced expression of TGF-␤ ligands (37) and receptors (38) and the activation of Smads (39) . TGF-␤1, shown to function as a tumor suppressor in the prostatic epithelium (40, 88) , induces apo-ptosis of prostate epithelial cells through unresolved mechanisms (40, 41, 89) . In the current study, we examined this mechanism using the NRP-154 rat prostate adenocarcinoma cell line (42) . Bcl-xL was selected for several reasons from a number of proteins surveyed as candidate regulators of TGF-␤1-induced apoptosis in NRP-154 cells. We show that TGF-␤1 promotes loss of Bcl-xL protein and mRNA expression in NRP-154 cells, temporally preceding intranucleosomal DNA fragmentation. Retrovirally mutagenized NRP-154 clones specifically resistant to apoptosis induced by TGF-␤1 express significantly higher levels of Bcl-xL (43) . Finally, an immunohistochemical survey correlated increased Bcl-xL expression with high grade prostate carcinomas, suggesting that this may be a mechanism of apoptotic resistance leading to prostate carcinogenesis (44) .
To test our hypothesis that loss of Bcl-xL is required for the induction of TGF-␤1-induced apoptosis, we generated NRP-154 clones constitutively overexpressing Bcl-xL and demonstrate that these clones are resistant to TGF-␤1-induced apoptosis but not TGF-␤1-induced gene induction or cell cycle arrest. Because of conflicting hypotheses on how Bcl-xL blocks apoptosis, we investigated differences in Apaf-1-dependent activation of caspases 9 and 3 in S-100 cytosol and cytochrome c release between NRP-154 cells overexpressing Bcl-xL (NRPxL-1 and -5) and control cells (NRPxL-2 and -4). Coimmunoprecipitation revealed physical interaction between Bcl-xL and Apaf-1 in NRP-154 cells, but overexpressed Bcl-xL does not inhibit Apaf-1/cytochrome c/dATP-induced caspase activation. Clones overexpressing Bcl-xL are resistant to TGF-␤1-induced mitochondrial cytochrome c release and maintain mitochondrial integrity. Our data indicate that the antiapoptotic effect of Bcl-xL occurs through blocking mitochondrial release of cytochrome c and not by directly antagonizing Apaf-1-dependent activation of caspases 9 and 3.
MATERIALS AND METHODS
Cell Culture and Apoptosis-The NRP-154 cell line was established and maintained as described (42) . GM2 (Dulbecco's modified Eagle's medium/F12 medium containing 5% fetal bovine serum, 20 ng/ml epidermal growth factor, 0.1 m dexamethasone, 10 ng/ml cholera toxin, and 5 g/ml insulin) was used for passaging and transfection assays. Apoptosis assays were performed in GM3 (Dulbecco's modified Eagle's medium/F12 containing 1% calf serum, 15 mM HEPES, and 0.1 m dexamethasone) using 10 ng/ml TGF-␤1 or vehicle (4 mM HCl, 1 mg/ml bovine serum albumin) or 5 nM staurosporine in Me 2 SO. Human Bcl-xL cDNA was cloned into the NheI and XhoI sites of the episomal vector, pCEP4 (Invitrogen), to create pCEP4-Bcl-xL. NRPxL clones were generated by LipofectAMINE Plus TM (Life Technologies, Inc.)-mediated transfection of pCEP4 or a pCEP4-Bcl-xL and hygromycin (260 g/ml) selection. NRP-154 cells undergo ϳ95% apoptosis by 96 h of TGF-␤1 treatment. It has been determined that ϳ100% of floating cells are apoptotic by DNA laddering (41) , caspase activation by Western blot analysis (data not shown), and DAPI nuclear staining (see Fig. 3 , H and I); therefore, quantification of floating cells, along with DAPI staining, is an accurate measure of apoptosis in this system.
Colorimetric Assay for Caspase-9 Activation-NRP-154 cells were treated with TGF-␤1 or vehicle for 48 h. Cells were harvested and assayed according to the caspase-9 colorimetric assay instructions (R & D Systems). 150 g of protein were used per reaction and incubated for 1 h at 37°C.
Immunofluorescent Detection of Cytochrome c Release-NRPxL clones were plated in 8-well chamber slides (Nunc) and treated with TGF-␤1 or vehicle for 36 h. Mitochondria were labeled with 100 nM MitoTracker Red-CHO (Molecular Probes) for 30 min before fixation (3% paraformaldehyde/PBS for 30 min). Slides were incubated with mouse anti-cytochrome c IgG (1:200, PharMingen 6H2.B4) overnight and with donkey anti-mouse IgG-fluorescein isothiocyanate (1:100, Jackson Laboratory) for 1 h, both in 3% bovine serum albumin/PBS as described in Ref. 45 . Slides were mounted with anti-quench medium containing DAPI (VectorLabs) for nuclear costaining and quantification of fragmented nuclei. Digital images were captured with a Nikon E-800 microscope with a Diagnostic Spot RT camera and Metamorphosis software.
Immunoprecipitation and Western Blot Analysis-Immunoprecipitations were done as described (46) . Cells were treated with TGF-␤1 or vehicle for the indicated times, trypsinized, washed twice with cold PBS, and lysed in immunoprecipitation buffer (PBS with 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS) plus protease inhibitors (1 mg/ml 4-(2-aminoethyl)benzenesulfonyl fluoride, 2 g/ml aprotinin, 2 g/ml leupeptin, 200 nm sodium orthovanadate) on ice for 20 min. Cell lysates were clarified at 14,000 rpm for 10 min at 4°C and assayed for protein concentration using a BCA test (Pierce). Lysates were subjected to SDS-polyacrylamide gel electrophoresis under reducing conditions and transferred to nitrocellulose. Membranes were blocked with 5% milk in TBST (10 mM Tris, pH 7.4, 150 mM NaCl, 0.1% Tween 20), incubated with appropriate primary antibody diluted in TBST ϩ 5% milk, and incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (1:5000, Jackson Laboratory). Membranes were developed with either enhanced chemiluminescence (Pierce) or ECLϩ (Amersham Pharmacia Biotech). When ECLϩ was used, bands were quantified using a Molecular Dynamics STORM scanner and ImageQuant software. Antibodies were from Santa Cruz Biotechnology In Vitro Caspase Activation Assay-S-100 extracts were isolated as described, with a minor modification (47) . Cells were grown to 90% confluence in three 150-mm dishes and harvested by trypsinization. Cell pellets were washed four times with ice-cold PBS, and all residual PBS was removed. Each pellet was resuspended in 3 volumes of HB (10 mM HEPES, pH 7.5, 5 mM MgCl 2 , 0.67 mM dithiothreitol, 0.67 mM phenylmethylsulfonyl fluoride, and 50 g/ml each leupeptin, aprotinin, and antipain) and incubated on ice for 20 min. Suspensions were lysed through a 25 gauge needle, centrifuged at 12,500 ϫ g for 20 min at 4°C twice, and recentrifuged at 100,000 ϫ g for 60 min at 4°C. Extracts were then clarified through a 0.2-m pore filter and brought to 5% glycerol before storage at Ϫ80°C. To activate cytosol, 0.4 g of cytochrome c, EDTA, and dATP (final concentrations, 7.5 and 1 mM, respectively) were added and incubated 1 h at 37°C. Purified 6xHis-Bcl-xL (48), isolated using the pProEX1® system (Invitrogen), was pre-incubated in the S-100 cytosol at 20°C for 20 min before activation, where appropriate. Untransformed DH5␣ lysate was also purified on a nickel column to serve as a control for the caspase-9 activation assays (6xHis control eluate). Each reaction was assayed for active caspase-9 and -3 by LEHD-pNA cleavage and Western blot analysis, respectively, as described.
Northern Blot Analysis-Total RNA was purified with RNeasy (Qiagen) from cells treated with TGF-␤1 or vehicle for the indicated times, and 10 g/lane were separated through a 1% agarose-formaldehyde gel and transferred to Nitran. Blots were hybridized overnight with Bcl-xL or fibronectin cDNA 32 P-labeled probes under modified Church's Hybridization conditions (49) . Blots were scanned using a Molecular Dynamics STORM and quantified using ImageQuant software. All bands of interest were normalized to glyceraldehyde-3-phosphate dehydrogenase or 18 S.
Transient Transfection-Cells (2.0 ϫ 10 5 ) were plated overnight in 6-well dishes and transfected using a standard calcium phosphate coprecipitate method. The calcium phosphate-DNA coprecipitate was washed away, and the cells were glycerol-shocked (15% glycerol in 1ϫ HEPES-buffered saline) for 90 s. Cells were washed twice with PBS, allowed to recover overnight in GM3, and treated with TGF-␤1 or vehicle for 24 h. Luciferase activities were measured using the Promega dual luciferase assay kit and an ML3000 microtiter plate luminometer.
RESULTS

Regulation of Bcl-2 Proteins by TGF-␤1 in NRP-154
Cells-To identify cellular targets of TGF-␤1 signaling involved in the initiation and execution of apoptosis in NRP-154 cells, we studied the regulation by TGF-␤1 of a number of proteins involved in apoptosis, including several Bcl-2 family members (Bcl-xL, Bax, and Bcl-2, Fig. 1A ) reported to be involved in prostate tumorigenesis (44, 50, 51) . A time course Western blot analysis from 0 -48 h of TGF-␤1 treatment revealed that Bcl-xL showed the most marked regulation by TGF-␤1, being down-regulated 5-10-fold by 12 h of treatment (Fig. 1A) . Downregulation of Bcl-xL by TGF-␤1 also occurred at the mRNA level (Fig. 1B) , within 4 -8 h of TGF-␤1 treatment.
Transient Overexpression of Bcl-xL Inhibits TGF-␤1-induced
Apoptosis in a Dose-dependent Manner-Our observation that TGF-␤1 down-regulates Bcl-xL mRNA and protein suggested that loss of Bcl-xL is essential for TGF-␤1-induced apoptosis in NRP-154 cells. If so, prevention of this loss would be expected to protect cells from TGF-␤1-induced apoptosis. To test this, NRP-154 cells were transiently transfected with either pCEP4-Bcl-xL or pCEP4 and then treated with TGF-␤1 for 48 h. Following treatment, apoptotic cells were quantified. pCEP4-Bcl-xL offered dose-dependent protection from TGF-␤1-induced apoptosis, whereas pCEP4 had no effect on the ability of TGF-␤1 to induce apoptosis (Fig. 2) . Transfection of 2.0 g of pCEP4-Bcl-xL was optimal in this assay, giving 47% reduction in TGF-␤1-induced apoptosis. In addition, the basal level of apoptosis without TGF-␤1 treatment was reduced by 27% compared with 2.0 g of pCEP4 alone. These results suggest that abrogating TGF-␤-dependent loss of Bcl-xL can inhibit apoptotic cell death.
Stable Overexpression of Bcl-xL Blocks and Does Not Delay TGF-␤1-induced Apoptosis-To confirm the above result, NRP-154 clones stably expressing Bcl-xL or vector only were derived, by transfection with either pCEP4-Bcl-xL or pCEP4, respectively, followed by selection with hygromycin. Two of the derived clones, NRPxL-1 and -5, overexpress Bcl-xL protein by 34-and 49-fold over endogenous levels, respectively; and two clones, NRPxL-2 and -4, express only endogenous levels (Fig.  3A) . Treatment of NRP-154 cells with TGF-␤1 for 48 h downregulated Bcl-xL protein to almost undetectable levels (Fig. 1) . To assess whether overexpression of Bcl-xL by a cytomegalovirus promoter would protect against TGF-␤1-mediated loss of Bcl-xL, NRPxL clones were treated with TGF-␤1 or vehicle for 48 h and subjected to Western blot analysis. Fig. 3A shows abundant Bcl-xL protein in NRPxL-1 and -5 before and after treatment; conversely, in NRPxL-2 and -4, Bcl-xL protein was down-regulated by 81 and 89%, respectively (Fig. 3B) . Interestingly, NRPxL-1 and -5, which express Bcl-xL from a non-TGF-␤1-regulated cytomegalovirus promoter, also demonstrated impressive decreases in Bcl-xL protein expression (64 and 62%, respectively); however the remaining amount of Bcl-xL was still above untreated NRP-154 levels. This result suggests that the effect of TGF-␤1 on Bcl-xL expression requires transcriptional and possibly non-transcriptional mechanisms (Fig. 1B) .
Protection against TGF-␤1-induced apoptosis occurred in NRPxL-1 and -5 after 48 h of treatment (Fig. 3, G and J) . However, it is possible that Bcl-xL overexpression only tran- siently protected against TGF-␤1-induced apoptosis. To test this, we treated the NRPxL clones with TGF-␤1 for 96 h and showed that Bcl-xL overexpression protected NRPxL-1 and -5 from TGF-␤1-induced apoptosis (Fig. 3K) . In contrast, NRPxL-2 and -4 were not protected from TGF-␤1-induced apoptosis (Fig. 3, H, I , and K), suggesting that Bcl-xL down-regulation was essential for the initiation of apoptosis. For comparison, treatment of parental NRP-154 cells with TGF-␤1 for 96 h resulted in 86% apoptosis (Fig. 3K) . Furthermore, protection from TGF-␤1-induced apoptosis by Bcl-xL overexpression was apparent in both transient and stable assays, indicating that this effect is not due to clonal variation.
Overexpression of Bcl-xL Does Not Inhibit All TGF-␤1 Signaling or Staurosporine-induced Apoptosis-One possibility for apoptotic resistance may be that Bcl-xL over-expression inhibits all TGF-␤1 responses. Here, we show that the NRP-154 cells overexpressing Bcl-xL remain sensitive to fibronectin mRNA induction, a classical TGF-␤1 response (52, 53) , following treatment with TGF-␤1 for 24 h (Fig. 4A) . Quantification of the fibronectin band intensities revealed that overexpressing Bcl-xL clones (NRPxL-1 and -5) induced fibronectin mRNA to a higher degree than NRPxL-2 and -4 (Fig. 4A) .
Primary prostatic epithelial cells treated with TGF-␤1 arrest in G 0 /G 1 due to the sequestering of E2F transcription factors by the TGF-␤1-regulated phosphorylation of retinoblastoma proteins (54, 55) . Through binding sites within E2F-regulated promoters, this family of transcription factors regulates Sphase-regulatory genes responsible for cell cycle progression (56) . To test whether Bcl-xL clones remained sensitive to growth arrest by TGF-␤1, we examined the effect of TGF-␤1 on their E2F activity. Similar to parental NRP-154 cells, the NRPxL clones decreased activity of the E2F-responsive luciferase reporter (57) after 24 h of TGF-␤1 treatment (Fig. 4B) . Interestingly, NRPxL-1 and -5 can recover from TGF-␤1-induced growth arrest and regain E2F activity when TGF-␤1 is removed (data not shown). These results further confirm that Bcl-xL does not block all TGF-␤1 responses and suggests that TGF-␤1 induces cell cycle arrest and apoptosis through distinct pathways.
The ability of Bcl-xL to block staurosporine-induced apoptosis was studied in this system. Treatment with 5 nM staurosporine caused both the Bcl-xL-overexpressing and control NRPxL clones to display morphological changes associated with apoptosis in less than 6 h and complete death within 48 h (Fig. 4C) . These data suggest that Bcl-xL selectively regulates apoptosis induced by TGF-␤1 and does not protect from staurosporine-induced death in NRP-154 cells.
Overexpression of Bcl-xL Blocks the Cleavage of Latent Caspase-9, Caspase-3, and Intact Poly(ADP-ribosyl)polymerase (PARP) Induced by TGF-␤1-Executioner
caspases (e.g. caspase-3) are activated in the initiation phase of apoptosis by an Apaf-1/caspase-9/dATP/cytochrome c complex and assist in the orchestrated disassembly of cellular proteins. PARP, a caspase-3 cleavage substrate, is a 116-kDa modular nuclear protein involved in DNA repair, usually in response to environmental stress (58) . In NRP-154 cells, we have observed that TGF-␤1 activates caspases 9 and 3, cleaves PARP, induces the expression of latent caspase-3, and inhibits the expression of intact PARP (data not shown). We examined whether Bcl-xL overexpression could interfere with these TGF-␤1-regulated effects. After 48 h of TGF-␤1 treatment, caspase-9 activity was assayed by LEHD-pNA cleavage. NRPxL-1 and -5 failed to activate caspase-9 in response to TGF-␤1, whereas NRPxL-2 and -4 demonstrated significant caspase-9 activity (5-and 10-fold increases, respectively) (Fig. 5A) . Western blot analysis revealed that NRPxL-1 and -5 were also not able to activate latent caspase-3 (Fig. 5B, upper panel) or cleave PARP to an inactive 85-kDa fragment (Fig. 5B, lower panel) in response to TGF-␤1, whereas NRPxL-2 and -4 showed significant caspase-3 activation and PARP cleavage. In contrast to cleavage of caspase-3 and PARP, Bcl-xL did not inhibit the TGF-␤1-induced expression of latent caspase-3 or down-regulation of intact PARP.
Bcl-xL Interacts with Apaf-1 but Does Not Inhibit Apaf-1-dependent in Vitro Activation of Caspases 9 and 3-Several studies imply that Bcl-xL inhibits apoptosis through interaction FIG. 4. Overexpression of Bcl-xL does not block TGF-␤1-induced fibronectin induction, cell cycle arrest, or staurosporine-induced apoptosis.
A, Northern blot analysis using total RNA harvested from NRPxL clones treated with TGF-␤1 or vehicle for 24 h. The blot was hybridized overnight with a rat fibronectin cDNA 32 P-labeled probe. Bands were visualized using a Molecular Dynamics Storm and normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH). B, NRPxL clones were transiently cotransfected with an E2F-responsive luciferase reporter and cytomegalovirus-renilla, treated with TGF-␤1 or vehicle, and harvested for luciferase measurements 24 h later. R.L.U., relative luciferase units. C, NRPxL clones were treated with 5 nM staurosporine (ST) or vehicle for 48 h before apoptotic cells were quantified. Each point represents the average of triplicate determinations Ϯ S.D.
with Apaf-1 and pro-caspase-9 in a ternary complex termed the apoptosome (59) . Recent attempts to define the fundamental role of Bcl-xL in this complex by the addition of free or epitopetagged Bcl-xL protein with epitope-tagged Apaf-1 have lead to conflicting results (36, 60) . However, there is no study on endogenous Bcl-xL and Apaf-1-dependent activation of latent caspase-9 or downstream caspases.
We first determined whether an interaction between Bcl-xL and Apaf-1 occurs in parental NRP-154 cells. Cells were transiently transfected with Bcl-xL-Flag and ϩ/ϪApaf-1-myc, and lysates immunoprecipitated against Bcl-xL-Flag were blotted for Apaf-1-myc and Bcl-xL-Flag. Fig. 6A shows that Apaf-1-myc interacted with Bcl-xL-Flag in NRP-154 cells, suggesting that Bcl-xL may offer protection against TGF-␤1-induced apoptosis by directly antagonizing Apaf-1-dependent caspase activation. To test this hypothesis, the ability of cytochrome c to initiate Apaf-1-dependent processing of latent caspases 9 and 3 was examined in S-100 cytosols prepared from untreated NRPxL clones. These cytosols were treated with cytochrome c and dATP at 37°C for 60 min, and the activation of caspases 9 and 3 was assayed by colorimetric cleavage of LEHD-pNA and Western blot analysis, respectively. As shown in Fig. 6B , all of the NRPxL clones were able to activate latent caspase-9 upon addition of cytochrome c and dATP to similar degrees, independent of Bcl-xL expression levels. Accordingly, no difference was observed in the activation of latent caspase-3 among the NRPxL clones, as demonstrated by the cleavage of latent caspase-3 to its catalytic p20/p17 subunits (Fig. 6C) . As a control, addition of dATP alone did not induce processing of latent caspases 9 or 3 (data not shown).
To confirm the above result and to rule out variation in the individual NRPxL clones, we chose to examine the effect of adding exogenous Bcl-xL to S-100 extracts. To accomplish this, S-100 cytosols were prepared from pooled populations of overexpressing NRPxL clones (seven different clones) and control NRPxL clones (five different clones), and 6xHis-Bcl-xL was purified from isopropyl-1-thio-␤-D-galactopyranoside-induced DH5␣ using the pProEX1® system. Because of unavoidable nonspecific binding to the nickel column during purification, 6xHis control eluate was also isolated from isopropyl-1-thio-␤-D-galactopyranoside-treated DH5␣ cells. To ensure that the 6xHis-Bcl-xL was properly translated and folded, it was added to control S-100 cytosol and immunoprecipitated with an antipolyhistidine antibody. Fig. 6D demonstrates that 6xHis-BclxL coimmunoprecipitated with endogenous Apaf-1, consistent with the coimmunoprecipitation data in Fig. 6A , thus supporting the notion that purified 6xHis-Bcl-xL was functionally active. 6xHis-Bcl-xL was then added to the control NRPxL cytosol at 5-, 10-, or 50-fold over endogenous levels, prior to caspase-9 activation with cytochrome c/dATP. As shown in Fig. 6E , the addition of 6xHis-Bcl-xL (or 6xHis control eluate) did not abrogate cytoplasmic pro-caspase-9 activation in the control NRPxL S-100 pool. In addition, to determine whether the lack of inhibition by Bcl-xL on pro-caspase-9 processing was a peculiarity of the NRPxL clones, HL-60 S-100 cytosol was treated similarly with 6xHis-Bcl-xL. Consistent with the NRPxL data, cytochrome c-dependent activation of pro-caspase-9 in HL-60 S-100 cytosol was not inhibited by 6xHis-Bcl-xL. These data suggest that Bcl-xL does not inhibit Apaf-1 or any other protease responsible for the activation of latent caspase-9 and subsequent activation of latent caspase-3.
TGF-␤1-induced Mitochondrial Cytochrome c Release Is
Inhibited by Bcl-xL Overexpression-To test an alternative hypothesis of how Bcl-xL protects against TGF-␤1-induced apoptosis, the role of mitochondrial cytochrome c release was examined. Bcl-xL localizes to the outer mitochondrial membrane, suggesting that it is a regulator of apoptosis through mitochondrial pathway(s) (25) . TGF-␤1-induced cytoplasmic accumulation of cytochrome c has been demonstrated in other systems but not in intact prostate epithelial cells (61, 62) .
NRPxL clones were treated with TGF-␤1 or vehicle for 36 h before labeling with 100 nM MitoTracker Red. Cells were then fixed, permeabilized, and probed for cytochrome c, and the nuclei were costained with DAPI. This technique allowed us to follow the localization of cytochrome c (fluorescein isothiocyanate), mitochondrial integrity (Red), and other events such as nuclear condensation (DAPI) (Fig. 7A) . Vehicle-treated clones exhibited complete mitochondrial colocalization of cytochrome c and MitoTracker Red (Fig. 7, B-E) . Following TGF-␤1 treatment, NRP-154 cells (data not shown) and NRPxL-2 and -4 lost mitochondrial colocalization of cytochrome c and MitoTracker Red labeling (Fig. 7, G and H, respectively) , indicative of cytochrome c release and breakdown of the mitochondrial respiratory chain. TGF-␤1-treated NRPxL-1 and -5, however, maintained colocalization of cytochrome c (Fig. 7, F and I,  respectively) , indicating that Bcl-xL overexpression prevents the cytoplasmic accumulation of cytochrome c and loss of mitochondrial integrity.
DISCUSSION
In the present study, we provide evidence that TGF-␤1 induces apoptosis through the down-regulation of Bcl-xL, cytochrome c release, and subsequent activation of caspases 9 and 3. When Bcl-xL-overexpressing NRP-154 cells are treated with TGF-␤1, they display resistance to TGF-␤1-induced cytochrome c release and caspase-9 and -3 activation yet remain sensitive to other TGF-␤1 responses (e.g. fibronectin induction, cell cycle arrest, induction of latent caspase-3, and loss of PARP expression).
Many of the cell lines (e.g. DU-145 and LNCaP) used to define the mechanisms of TGF-␤1-induced apoptosis in the prostate were isolated from distant metastases, display variances to endocrine stimuli, and lack intact TGF-␤1-signaling pathways (40, 63-67). These characteristics limit the study of normal cellular responses to critical factors within the prostatic milieu. The cell line used in this study, NRP-154, was derived from the pre-neoplastic dorsal-lateral prostate of a Lobund/ Wistar rat (42), a recognized model of prostate carcinogenesis due to their unusually high incidence of spontaneous cancers of the male reproductive tract (68) . NRP-154 cells have a luminal epithelial phenotype with respect to cytokeratin markers, growth factor responses, and relatively low Bcl-2 expression and undergo growth inhibition and robust apoptosis when treated with TGF-␤1 (41, 42) .
The cellular targets implicated in TGF-␤1-induced apoptosis are unique to the tissue and cell type examined (69, 70) . We report for the first time that TGF-␤1 activates latent caspases 9 and 3 (Fig. 5, A and B) in prostate epithelial cells. TGF-␤1 has been shown to activate caspase-3 in several other systems (70 -74) but has not been confirmed in any other prostatic cell line. In Fig. 5B we showed the appearance of the p17 catalytic fragment (Fig. 5B, upper panel) and confirmed caspase-3 activity by detection of the caspase-3 cleavage fragment (p85) of PARP (Fig. 5B, lower panel) . Not expected, and to our knowledge unreported, was the induction of latent caspase-3 expression (Fig. 5B, upper panel) and the down-regulation of PARP expression (Fig. 5B, lower panel) by TGF-␤1. These observations further support the involvement of transcriptional activity by TGF-␤1 to enhance apoptosis. However, unlike their cleavage induced by TGF-␤1, regulation of caspase-3 and PARP expression was not blocked by Bcl-xL overexpression.
The release of cytochrome c by TGF-␤1 in the prostate has been implied by cytochrome c-dependent activation of caspases but never demonstrated (40) . We observed that Bcl-xL protected NRP-154 cells from TGF-␤1-induced mitochondrial cytochrome c release and loss of mitochondrial integrity (Fig. 7, E  and H) . Bcl-xL has been reported to protect against apoptotic cell death in several cell lines by various other inducers through preventing cytochrome c release (31, 32, (75) (76) (77) . However, other potential molecular mechanisms for the inhibition of apoptosis by Bcl-xL have been proposed. For example, verteporfin-photosensitized HeLa cells with enforced overexpression of Bcl-xL are not resistant to cytochrome c release, demonstrating that Bcl-xL protection may be inducer-or cell/tissue type- Samples were subjected to SDS-polyacrylamide gel electrophoresis and immunodetected using anti-Bcl-xL and anti-myc antibodies. B and C, cytochrome c, dATP, and EDTA were added to S-100 cytosol of NRPxL clones and incubated at 37°C for 1 h before analyses; caspase-9 activity was determined by colorimetric LEHD-pNA cleavage (B), and caspase-3 activation was demonstrated by cleavage to its catalytic subunits, p20/p17, by Western blot analysis (C). D, purified 6xHis-Bcl-xL was incubated with control NRPxL S-100 cytosol and pre-cleared with non-immunized mouse IgG before immunoprecipitation (IP) with anti-polyhistidine IgG. Samples were subjected to SDS-polyacrylamide gel electrophoresis and immunodetected using anti-Bcl-xL and anti-Apaf-1 antibodies. E, S-100 cytosols were isolated from pooled populations of Bcl-xL-overexpressing NRPxL clones and control NRPxL clones. Control NRPxL S-100 cytosol was pre-incubated with various (expressed as -fold over endogenous levels of Bcl-xL) amounts of 6xHis-Bcl-xL (or 6xHis control eluate) prior to activation with cytochrome c and dATP. Activated and non-activated cytosols from Bcl-xLoverexpressing NRPxL cells and HL-60 cells (pre-incubated with 6xHis-Bcl-xL or 6xHis control eluate) are shown as control. Each point represents the average of triplicate determinations Ϯ S.D. A representative blot of at least three independent experiments is shown. dependent (78) .
The observation that Bcl-xL overexpression did not inhibit staurosporine-induced apoptosis was unexpected. This contrasts with several studies where enforced Bcl-xL expression inhibited staurosporine-induced apoptosis in prostate epithelial cells (79 -81) . Additional work revealed that the NRP-154 and NRP-152 (41) cell lines and NRPxL clones are exquisitely sensitive to staurosporine treatment; concentrations between 2 and 5 nM induce apoptotic morphology in Յ6 h. The staurosporine concentrations used in the studies mentioned above were 100 -800-fold greater than necessary for apoptosis in NRP-154 cells, suggesting different mechanisms for staurosporine-induced apoptosis. Such differences may be attributed to the derivation of the NRP-154 and NRP-152 cell lines from primary tissues rather than from tumors or distant metastases. Moreover, several reports indicate that Bcl-xL is not regulated by staurosporine treatment and that cytochrome c release occurs in the presence of constitutively expressed endogenous Bcl-xL (80, 82) , further supporting the notion that Bcl-xL may not regulate staurosporine-induced apoptosis in certain cases.
Genetic studies have identified CED-3, -4, and -9 as important components in the cell death machinery of C. elegans. Wu et al. (46) demonstrated that the pro-survival gene product of ced-9 regulates CED-4 activity by direct interaction. Further work has confirmed that CED-9 and CED-3 interactions with CED-4 regulate apoptosis (83) . A similar complex was identified in mammalian cells between Apaf-1 and caspase-9 (CED-4 and CED-3 homologues) that is antagonized by Bcl-xL, as shown by the inhibition of in vitro Apaf-1-dependent caspase-9 processing (36, 59) . Aven, an inhibitor of Apaf-1 self-association and caspase-9 activation, was identified through a yeast twohybrid screen as a Bcl-xL-interacting partner, providing further evidence that Bcl-xL is a regulator of the apoptosome (84) . Bcl-xL has also been shown to inhibit apoptosis in cells microinjected with cytochrome c, suggesting a level of protection beyond mitochondrial cytochrome c release (85) . However, other work has been unable to detect interactions between Bcl-xL and Apaf-1 by coimmunoprecipitation studies and propose that Bcl-xL does not antagonize Apaf-1-dependent caspase-9 activation (60). Thus, the interaction between Bcl-xL and Apaf-1 may be dependent on cell type, unidentified protein participants, or immunoprecipitation/buffer stringency conditions. Even so, in our system an interaction between Bcl-xL and Apaf-1 was detected by coimmunoprecipitation. Published observations on Bcl-xL antagonizing Apaf-1 function were concluded by the addition/titration of purified or epitope-tagged Bcl-xL to cytosolic extracts. We were interested in observing whether Bcl-xL overexpression within our clones, shown to bind Apaf-1 (Fig. 6C) , could inhibit Apaf-1-dependent caspase processing in S-100 cytosol. As shown in Fig. 6 , B and C, Apaf-1-dependent activation of caspases 9 and 3 was not antagonized by endogenous Bcl-xL overexpression, suggesting that Bcl-xL cannot offer protection at the apoptosome in this system. Moreover, the addition of purified 6xHis-Bcl-xL, which also associated with Apaf-1, or the 6xHis control had no effect on pro-caspase-9 activation in both the pooled control NRPxL and HL-60 S-100 cytosols (Fig. 6E) .
The use of S-100 cytosol to study the role of Bcl-xL on the apoptosome may appear impractical due to the localization of Bcl-xL to the outer mitochondrial membrane. However, all S-100 cytosols in this study contain Bcl-xL but no mitochondrial cytochrome c contamination by Western blot analysis (data not shown). Cytosolic Bcl-xL has been shown to migrate to the mitochondrial membrane upon the induction of apoptosis in murine thymocytes (86) . However, membrane insertion does not appear to be necessary for its antiapoptotic function, because truncation of the C-terminal hydrophobic tail of Bcl-xL does not affect its pro-survival activity (26) . Even though Bcl-xL can interact with Apaf-1, as shown by both cotransfection (Fig. 6A ) and exogenous addition (Fig. 6D ) studies, the function of this interaction remains elusive.
It has been demonstrated through immunohistochemical examination that nearly all prostate tumors derived from patients sustain Bcl-xL expression (44, 87) . Importantly, many have increased expression of Bcl-xL occurring at the adenoma to carcinoma transition and continuing through development of metastases. As shown in Fig. 4A , NRPxL-1 and -5 hyperinduce fibronectin mRNA, suggesting that TGF-␤1-signaling pathways may be enhanced or atypical when apoptosis cannot be initiated. The ability of cells to increase sensitivity to classical TGF-␤1 responses (gene induction) in the presence of high Bcl-xL levels, while resistant to apoptosis, proposes engaging roles of antiapoptotic factors in TGF-␤1 signal transduction. Further work to completely identify what factors within the prostate regulate TGF-␤1 signals will enhance our understand- ing of normal prostate biology and assist in appropriate intervention when cellular signaling goes awry.
